Inclusion Criteria:

- Premenopausal patients with histologically verified, lymph node-negative (pT1c-pT3)
or lymph node-positive (pT1a-pT3) breast cancer

- Hormone receptor-positive status

- More than 6 histologically examined lymph nodes

- Laboratory parameters

1. hematopoiesis: > 3500/l leukocytes, > 100,000/l thrombocytes

2. renal function: creatinin < 1.5mg%

3. hepatic function: GOT
4. bilirubin: < 1.5mg %

5. metabolic parameters: Na, Ca, K in normal range, normal level of blood sugar

6. blood coagulation: PZ > 60%

- Concluded healing process following surgery

-
- Informed consent

Exclusion Criteria:

- T4 carcinoma; inflammatory breast cancer, carcinoma in situ

- Simultaneous or sequential bilateral breast cancer

- Preoperative tumor-reducing radiotherapy or preoperative tumor-specific medical
treatment

- Male patients

- Pregnancy or lactation

- Lacking compliance or understanding of the disease

- General contraindication against cytostatic treatment

- Serious concomitant disease preventing implementation of adjuvant therapy or regular
follow-up

- Second carcinoma or status post second carcinoma (except for curatively treated
squamous cell carcinoma of the skin or cervical carcinoma in situ)